<DOC>
	<DOCNO>NCT00127920</DOCNO>
	<brief_summary>The likely way improve survival cure rate treat ovarian cancer , fallopian tube epithelial cancer , peritoneal cancer maximal `` upfront '' therapy ( Morrow &amp; Curtin , 1998 ) . This involve optimal primary tumor debulking surgery . The active chemotherapy agent promptly administer . Taxol Carboplatin Cisplatin become standard '' first line '' therapy proven survival benefit regimens treat advanced ovarian adenocarcinoma patient . New chemotherapy agent like bevacizumab demonstrate increase overall progression free survival benefit metastatic colorectal cancer patient study potential contributory impact current standard treatment . Since triplet regimen demonstrate compelling superiority , combination taxol , carboplatin , bevacizumab intriguing potential synergy , distinct mechanism action , non-overlapping toxicity . The null hypothesis ( Ho ) drug regimen demonstrate 80 % patient response rate ( RR ) . The alternative Hypothesis ( H1 ) : The triplet drug regimen demonstrate significantly high patient response rate standard therapy . Hypothesis ( H2 ) : The triplet drug regimen demonstrate significantly favorable patient time tumor progression rate standard therapy .</brief_summary>
	<brief_title>Pilot Study Taxol , Carboplatin , Bevacizumab Advanced Stage Ovarian Carcinoma Patients</brief_title>
	<detailed_description>The likely way improve survival cure rate treat ovarian cancer , fallopian tube epithelial cancer , peritoneal cancer maximal `` upfront '' therapy . This involve optimal primary tumor debulking surgery . The active chemotherapy agent promptly administer . Taxol Carboplatin Cisplatin become standard '' first line '' therapy proven survival benefit regimens treat advanced ovarian adenocarcinoma patient . New agent like bevacizumab ( Avastin ) , demonstrate increase overall progression free survival benefit metastatic colorectal cancer patient , add optimal first line ovarian chemotherapy regimen hop see improvement progressive free interval over-all survival . Since triplet regimen demonstrate compelling superiority , combination taxol , carboplatin , bevacizumab ( Avastin ) intrigue potential synergy , distinct mechanism action , non-overlapping toxicity .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subjects histologic cytologic diagnosis stage III/IV ovarian cancer , fallopian tube epithelial cancer , peritoneal cancer receive prior chemotherapy radiotherapy . Subjects must appropriate surgery gynecologic cancer . However , subject may treat neoadjuvant manner , surgery perform chemotherapy cycle 1 , 2 , 3 . If neoadjuvant therapy administer , subject must receive first dose six week postoperatively . Subjects must adequate bone marrow , renal hepatic function define WBC &gt; 3,000 cells/cu ml. , platelet &gt; 100,000/cu.ml. , calculate creatinine clearance &gt; 50 ccs/min. , bilirubin &lt; 1.5 mg/dl , SGOT &lt; three time normal . Karnofsky performance status &gt; 50 % . Subjects sign institutional review board ( IRB ) approve informed consent form . Subjects epithelial ovarian cancer low malignancy potential . Subjects septicemia , severe infection , acute hepatitis . Subjects severe gastrointestinal bleeding . Subjects history congestive heart failure , angina , history myocardial infarction within past six month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>